8-K: Citius Oncology Faces Nasdaq Delisting Threat Due to Low Share Price

Citius Oncology has been notified by Nasdaq that its stock price has fallen below the required $1.00 minimum, potentially leading to delisting if compliance isn't regained by October 20, 2025.

Summary

• Citius Oncology received a notification from Nasdaq on April 23, 2025, stating that its common stock price has been below $1.00 for 30 consecutive business days, violating Nasdaq's minimum bid price rule.
• The company has until October 20, 2025, to regain compliance by having its stock price close at or above $1.00 for at least ten consecutive business days.
• If compliance isn't achieved by the initial deadline, Citius Oncology may be eligible for an additional 180-day compliance period, contingent on meeting other listing requirements and proposing a plan to address the bid price deficiency, potentially through a reverse stock split.
• Failure to regain compliance could result in delisting from the Nasdaq Capital Market, although the company has the right to appeal such a decision.
• Citius Oncology is currently assessing its options to regain compliance with the Nasdaq listing rules, but there is no guarantee of success.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting warning, indicating potential financial instability and uncertainty for investors. While the company has time to regain compliance, the situation presents a significant risk.

Positives

• The notification has no immediate effect on the listing of Citius Oncology's common stock.
• The company has a compliance period until October 20, 2025, to regain compliance.
• There is a possibility of an additional 180-day compliance period.
• The company has the right to appeal a delisting determination.

Negatives

• Citius Oncology's stock price has been below $1.00 for 30 consecutive business days.
• The company faces potential delisting from the Nasdaq Capital Market.
• There is no assurance that the company will regain compliance with the Bid Price Rule.

Risks

• Failure to regain compliance with the Nasdaq's minimum bid price rule could lead to delisting.
• The company's stock price may continue to decline, making it difficult to regain compliance.
• The company may need to implement a reverse stock split, which could negatively impact shareholders.
• There is no guarantee that the company will maintain compliance with other Nasdaq continued listing requirements.

Future Outlook

Citius Oncology is evaluating its options for regaining compliance with Nasdaq listing rules, but there is no assurance of success.

Management Comments

• Leonard Mazur, Chairman and Chief Executive Officer, signed the report on behalf of Citius Oncology.

Industry Context

Delisting notices are not uncommon for companies in the biotechnology sector, especially those in the development stage that may face challenges in maintaining a stable stock price. Companies in similar situations often explore options such as reverse stock splits, attracting new investment, or demonstrating significant clinical or commercial progress to boost investor confidence.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with maintaining Nasdaq listing requirements.
• Reverse stock splits are a common strategy employed by companies in this situation, although they can be viewed negatively by investors.
• Companies like Geron Corporation and BioTime (now Lineage Cell Therapeutics) have faced similar delisting warnings in the past and have taken various measures to regain compliance.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment.
• Employees may face uncertainty about the company's future.
• The company's ability to raise capital may be impaired.

Next Steps

• Citius Oncology will evaluate its options for regaining compliance with Nasdaq listing rules.
• The company may need to implement a reverse stock split.
• The company may need to attract new investment.
• The company may need to demonstrate significant clinical or commercial progress.

Key Dates

Keywords

Nasdaq, delisting, compliance, bid price rule, Citius Oncology, CTOR, stock price